BridgeMD
New treatment option for Stroke
Official title Neurophysiological and Behavioral Effects of Combining Transcranial Direct Current Stimulation (tDCS) and Modified-Constraint Induced Movement Therapy (mCIMT)
ClinicalTrials.gov ID: NCT06786000
What this study is testing
- What it's testing
- This clinical trial aims to evaluate the effect of different types of tDCS modulation with mCIMT in improving affected upper-limb motor function for stroke patients. The main question it seeks to answer: Which type of tDCS (bi-hemispheric, anodal, or cathodal) combined with the mCIMT program leads to greater improvement in affected upper-limb function in patients with stroke?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult participants clinically diagnosed and confirmed by imaging of ischemic or hemorrhagic cerebrovascular accident (Dahl et al., 2008; Jin et al...
- Participant's age older than 18 years (Baltar et al., 2020).
- Stroke onset more than 3 months with unilateral motor deficits (Lin et al., 2010).
- Adequate cognitive function is required to follow instructions. The Arabic version of the Mini Mental State Examination (MMSE) should be ≥24 (Kim...
- 10° of active extension to the metacarpophalangeal and interphalangeal joints and 20° at wrist will be assessed by manual goniometer (Dahl et al...
You likely can't join if
- Severe muscle spasticity at the affected limb at all joints (the Modified Ashworth Scale scores \> 3) (Baltar et al., 2020).
- Contraindications to NIBS (Bornheim et al., 2019).
- Unilateral neglect (Dahl et al., 2008)
- Other neurologic or orthopedic conditions that may affect hand function.
- Unstable medical conditions.
See the full eligibility criteria
- Adult participants clinically diagnosed and confirmed by imaging of ischemic or hemorrhagic cerebrovascular accident (Dahl et al., 2008; Jin et al., 2019).
- Participant's age older than 18 years (Baltar et al., 2020).
- Stroke onset more than 3 months with unilateral motor deficits (Lin et al., 2010).
- Adequate cognitive function is required to follow instructions. The Arabic version of the Mini Mental State Examination (MMSE) should be ≥24 (Kim, 2021).
- 10° of active extension to the metacarpophalangeal and interphalangeal joints and 20° at wrist will be assessed by manual goniometer (Dahl et al., 2008).
- Fugl-Meyer assessment (FMA) scores between 19 and 58, indicating moderate to mild impairments.
- Not participating in other clinical, or research studies at the same time.
- Severe muscle spasticity at the affected limb at all joints (the Modified Ashworth Scale scores \> 3) (Baltar et al., 2020).
- Contraindications to NIBS (Bornheim et al., 2019).
- Unilateral neglect (Dahl et al., 2008)
- Other neurologic or orthopedic conditions that may affect hand function.
- Unstable medical conditions.
The study team makes the final eligibility decision.
Where it's taking place
- Riyadh, Riyadh Region, Saudi Arabia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Riyadh, Riyadh Region, Saudi Arabia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.